Current stock page

Financial Data

INBX Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

INBXInhibrx Biosciences Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

BearishEdge 6/10
$83.30−$4.45 (−5.07%)

Latest quote

  • Momentum
    50
  • Value
    —
  • Quality
    28
  • Risk resilience
    40
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$2M$0$0$0$0$1.3M$0$100K
Gross Profit$0$0-$537K-$564K-$582K$638K-$675K-$589K
Operating Income-$31.74M-$32.15M-$30.93M-$30.92M-$33.81M-$27.39M-$42.9M-$49.93M
Net Income-$38.73M-$36.65M-$33.44M-$32.83M-$35.26M-$28.65M-$43.31M-$47.87M
EPS-$2.46-$2.34-$2.15-$2.11-$2.28-$1.85-$2.8-$3.31
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$34.61M-$29.92M-$38.03M-$30.12M-$33.82M-$29.95M-$35.9M-$43.72M
Capital Expenditure-$56K$27K$0$0-$10K$0-$21K-$16K
Free Cash Flow-$34.66M-$29.89M-$38.03M-$30.12M-$33.83M-$29.95M-$35.92M-$43.74M
Net Cash Provided By Operating Activities-$34.61M-$29.92M-$38.03M-$30.12M-$33.82M-$29.95M-$35.9M-$43.72M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$220.29M$154.22M$183.97M$146.48M$177.47M$212.12M$242.64M$180.77M
Total Debt$0$5.34M$5.9M$107.01M$6.99M$106.79M$106.53M$8.05M
Cash And Cash Equivalents$199.47M$133.34M$161.66M$124.22M$153.09M$186.57M$216.52M$152.6M
Total Liabilities$306.17M$207.2M$205M$138.49M$140.64M$143.56M$148.2M$47.18M
Total Stockholders Equity-$85.88M-$52.98M-$21.04M$7.99M$36.83M$68.56M$94.44M$133.58M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio——————0.10.12
P/B ratio———125.6931.365.321.781.51
P/S ratio654.74———————
Debt To Equity———13.390.191.561.130.06
Free Cash Flow Yield-10.13%-8.68%-7.29%-12.92%-12.42%-38.44%-100.64%-97.63%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio——————0.10.12
P/B ratio———125.6931.365.321.781.51
P/S ratio654.74———————
Return On Equity———-17.52%-4.21%-238.76%18.24%12.63%
Debt To Equity———13.390.191.561.130.06

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-9.19x
Pb-15.25x
EPS Growth Yoy-7.89%
Gross Margin-55.05%
Operating Margin-6286.70%
ROE373.04%
ROIC-73.03%
Debt To Equity0
FCF Yield-10.82%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$83.30
Volume245,898
RSI (14)45.11
MACD-2.14
MACD signal-3.27
MACD histogram1.13
ADX (14)14.16
SMA (50)$95.27
SMA (200)$92.69
ATR (14)$6.80
Historical volatility (annualized)120.87%
Volume (20-day average)303,291

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score40/100
Beta2.18
Annual volatility82.28%
Max Drawdown-49.39%
Sharpe Ratio0.49
VaR (95%, 1-day)-6.28%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

INBX Financial Data FAQ

What is Inhibrx Biosciences Inc.'s revenue?

Inhibrx Biosciences Inc.'s revenue is one of the core financial data points for INBX. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Inhibrx Biosciences Inc.'s revenue growing?

Revenue growth shows whether Inhibrx Biosciences Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is INBX's EPS?

INBX's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Inhibrx Biosciences Inc.'s net income?

Inhibrx Biosciences Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Inhibrx Biosciences Inc. generate?

Free cash flow shows how much cash Inhibrx Biosciences Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Inhibrx Biosciences Inc. have?

Cash and debt help frame INBX's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.